TherapeuticsMD (DB:29TA) - Cotización, noticias y análisis

Resumen de acción 29TA

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States.

29TA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 18.48%

Análisis de riesgos

Acciones altamente ilíquidas

Patrimonio neto negativo

No tiene una capitalización bursátil significativa (€58M)

Los accionistas han sido diluidos en el último año

+ 1 riesgos adicionales

Competidores de TherapeuticsMD, Inc.

SynBiotic

DUSE:SBX

€46.8m

Apontis Pharma

XTRA:APPH

€67.1m

Pierrel

DB:2FJ0

€92.8m

MPH Health Care

DB:93M1

€85.6m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for TherapeuticsMD
Historical stock prices
Current Share Price	US$9.75
52 Week High	US$34.75
52 Week Low	US$0.11
Beta	1.43
1 Month Change	0%
3 Month Change	1.56%
1 Year Change	-67.50%
3 Year Change	-94.13%
5 Year Change	-95.37%
Change since IPO	-95.21%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	29TA	DE Pharmaceuticals	Mercado DE
7D	0%	-3.3%	-1.5%
1Y	-67.5%	-30.8%	0.9%

Rentabilidad vs. Industria: 29TA obtuvo unos resultados inferiores a los del sector German Pharmaceuticals , que el año pasado arrojó un rendimiento del -28.2%.

Rentabilidad vs. Mercado: 29TA obtuvo unos resultados inferiores a los del mercado German, que fue del 5.9% el año pasado.

Volatilidad de los precios

Is 29TA's price volatile compared to industry and market?
29TA volatility
29TA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: 29TA no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 29TA en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2008	416	Brian Bernick	www.therapeuticsmd.com

Resumen de fundamentos de TherapeuticsMD, Inc.

¿Cómo se comparan los beneficios e ingresos de TherapeuticsMD con su capitalización de mercado?
Estadísticas fundamentales de 29TA
Capitalización bursátil	€58.33m
Beneficios(TTM)	-€27.21m
Ingresos (TTM)	€92.29m

0.6x

Ratio precio-ventas (PS)

-2.1x

Ratio precio-beneficio (PE)

¿Está 29TA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 29TA
Ingresos	US$91.98m
Coste de los ingresos	US$19.62m
Beneficio bruto	US$72.36m
Otros gastos	US$99.48m
Beneficios	-US$27.12m

Últimos beneficios comunicados

Jun 30, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.86
Margen bruto	78.67%
Margen de beneficio neto	-29.49%
Ratio deuda/patrimonio	-348.3%

¿Cómo se ha desempeñado 29TA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 29TA

Recompensas

Análisis de riesgos

Competidores de TherapeuticsMD, Inc.

DUSE:SBX

€46.8m

XTRA:APPH

€67.1m

DB:2FJ0

€92.8m

DB:93M1

€85.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Recent updates

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index

TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners

Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million.

Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera®

First quarter 2022 earnings released: US$5.69 loss per share (vs US$5.67 loss in 1Q 2021)

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Forecast breakeven date pushed back to 2024

GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million.

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair

Independent Director recently bought €510k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Forecast to breakeven in 2023

Executive Vice President of Operations Edward Borkowski has left the company

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Independent Director recently bought €619k worth of stock

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index

TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)

Revenue beats expectations

TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

New 90-day high: €1.31

TherapeuticsMD, Inc. Announces the Launch of Just Say Vagina to Encourage Women to Speak Clearly and Directly About Their Reproductive Health

New 90-day low: €0.94

New 90-day low: €1.03

Revenue beats expectations

Third quarter 2020 earnings released: US$0.12 loss per share

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

New 90-day low: €1.06

TherapeuticsMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Knight Therapeutics Inc and TherapeuticsMD, Inc. Announce Health Canada Approval of BIJUVA

First half earnings released

TherapeuticsMD, Inc. to Report Q2, 2020 Results on Aug 06, 2020

New 90-day high - €1.92

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from S&P Pharmaceuticals Select Industry Index

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de TherapeuticsMD, Inc.

0.6x

-2.1x

Beneficios e Ingresos